Author/Authors :
James R. Epperson، نويسنده , , Marc A. Bruce، نويسنده , , John D. Catt، نويسنده , , Jeffrey A. Deskus، نويسنده , , Donald B. Hodges، نويسنده , , George N. Karageorge، نويسنده , , Daniel J. Keavy، نويسنده , , Cathy D. Mahle، نويسنده , , Ronald J. Mattson، نويسنده , , Astrid A. Ortiz، نويسنده , , Michael F. Parker، نويسنده , , Katherine S. Takaki، نويسنده , , Brett T. Watson، نويسنده , , Joseph P.Yevich، نويسنده ,
Abstract :
A series of fluoren-9-yl ethyl amides (2) were synthesized and evaluated for human melatonin MT1 and MT2 receptor binding. N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]propanamide (2b) was selected and evaluated in functional assays measuring intrinsic activity at the human MT1 and MT2 receptors and demonstrated full agonism at both receptors. The chronobiotic properties of 2b were demonstrated in both acute and chronic rat models where 2b produced an acute phase advance of 32 min at 1 mg/kg and chronically entrained free-running rats with a mean effective dose of 0.23 mg/kg. Compound 2b is significantly less efficacious than melatonin in constricting human coronary artery.
